Please check your internet connection and try again.
# Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525250at
## Overview
Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525250at (nitroglycerin) is a potent vasodilator that acts primarily on venous smooth muscle.
## Primary Indications
* Angina pectoris (relief of acute episodes and prevention of exertional angina)
* Preoperative hypertension
## Adult Dosing
* **Angina Pectoris:**
* Sublingual tablet: 0.3 mg, 0.4 mg, or 0.6 mg taken at the onset of chest pain. May repeat every 5 minutes for up to 3 doses. If chest pain persists after 3 doses and medical attention is not available, seek immediate medical attention.
* Translingual spray: 1 or 2 metered doses sprayed under the tongue at the onset of chest pain. May repeat doses every 5 minutes. Do not exceed 3 doses in a 15-minute period.
* Transdermal patch/ointment: Varies by product; typically applied once daily for prevention.
* **Preoperative Hypertension:**
* Intravenous (IV): 5 mcg/min, titrated upward by 5 mcg/min every 5 minutes until desired blood pressure reduction is achieved. Maximum dose is typically 20 mcg/min, but may be higher based on clinical response and local protocol.
## Pediatric Dosing
* Information regarding pediatric dosing for Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525250at is limited. Use with caution and under close medical supervision if deemed necessary.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is recommended, but caution is advised due to potential for increased sensitivity.
* **Hepatic Impairment:** No specific dose adjustment is recommended, but caution is advised.
## Contraindications
* Hypersensitivity to nitroglycerin or other nitrates.
* Concurrent use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to the risk of severe hypotension.
* Severe anemia.
* Glaucoma (relative contraindication for sublingual formulations due to potential increase in intraocular pressure).
* Conditions where a rapid decrease in blood pressure may be detrimental (e.g., severe aortic stenosis, hypertrophic subaortic stenosis, constrictive pericarditis, cardiac tamponade).
## Adverse Effects
* **Common:** Headache, dizziness, lightheadedness, flushing, hypotension.
* **Serious:** Methemoglobinemia (especially with IV administration or in infants), syncope, reflex tachycardia.
## Key Drug Interactions
* **Phosphodiesterase-5 (PDE5) Inhibitors:** Potentially fatal hypotension. Avoid concurrent use.
* **Other Antihypertensives:** Additive hypotensive effects.
* **Alcohol:** Can potentiate hypotensive effects and flushing.
* **Dihydroergotamine:** May decrease nitroglycerin's antianginal effect and increase risk of ergotism.
## Monitoring
* Blood pressure and heart rate.
* Symptoms of angina.
* For IV administration: continuous ECG monitoring and invasive hemodynamic monitoring may be indicated.
* For IV infusions, monitor for signs of methemoglobinemia.
## Clinical Pearls
* Sublingual nitroglycerin should be kept in its original light-resistant container.
* Advise patients to sit down before taking sublingual nitroglycerin to prevent falls due to dizziness.
* Tolerance to transdermal nitroglycerin can develop; a nitrate-free interval (e.g., 10-12 hours daily) is often recommended for transdermal patches or ointment to prevent this.
* Do not crush or chew sublingual tablets.
***
*This information is intended for healthcare professionals and is not a substitute for consulting the most current prescribing information or local institutional protocols. Always verify the latest drug information before making clinical decisions.*
